Skip to main content
ISOP ACoP 2025 Annual Conference Main banner
ViewAttendees 3
Symposium

QSP/ PBPK

C2B - An immune booster: QSP modeling to advance the treatment for autoimmune diseases

Sunday, October 19, 2025
2:00 PM - 3:30 PM MDT
Location: Willow Lake 3 - 5

Disclosure(s):
Fei Hua, PhD: No financial relationships to disclose
Huilin Ma, PhD: No financial relationships to disclose
Justin S. Feigelman, Dr.rer.nat.: No financial relationships to disclose
Douglas W. Chung, M.S.: No financial relationships to disclose
Sai Phanindra Venkatapurapu, PhD: No financial relationships to disclose

Description of session (include background & scientific importance): Autoimmune diseases, characterized by the body’s immune system attacking its own tissue, represent a significant and growing burden on global healthcare systems. While the dysregulation of the immune systems is the underlying reason for these diseases in general, each disease has different pathological mechanisms. In addition, these diseases are driven by a complex interplay of immune pathways, genetic factors, and environmental triggers, making them difficult to treat and manage. The variability in patient responses further complicates therapeutic strategies, as no single treatment works universally across the diverse population.

Recent advancements in Quantitative Systems Pharmacology (QSP) offer a powerful approach to address these challenges. By integrating mechanistic insights of the disease biology, drug mechanism of action, and multi-scale data, QSP enables a more precise and personalized approach to autoimmune disease treatment.

This symposium will showcase the latest examples in QSP modeling to support the development of treatment for autoimmune diseases, including applications in target identification, biomarker discovery, clinical trial design, and emphasize the impact of QSP models in optimizing therapeutic strategies and improving patient outcomes. The session is also intended to provide a platform for discussion on challenges, opportunities, and future directions in applying QSP to autoimmune diseases.

Learning Objectives:

  • Participants will be able to understand the complexity of autoimmune diseases and the need for innovative approaches, learn how QSP models integrate mechanistic insights and multi-scale data, identify challenges and future directions in QSP modeling for autoimmune diseases, and apply QSP modeling to resolve real-world challenges in autoimmune disease research and drug development.

Presentations:

  • 2:00 PM - 2:20 PM MDT
    Integrated systems pharmacology modeling of severe asthma and the IL-33/ST2 pathway

    Speaker: Justin S. Feigelman, Dr.rer.nat. (he/him/his) – Gilead Sciences

  • 2:20 PM - 2:40 PM MDT
    Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores

    Speaker: Douglas W. Chung, M.S. (he/him/his) – Certara Applied BioSimulation, Sheffield, United Kingdom

  • 2:40 PM - 3:00 PM MDT
    Implementing QSP modeling in the clinical translation of mesenchymal stem cells in autoimmune diseases: a case study in lupus nephritis

    Speaker: Chen Zhao, Ph.D. – Nanjing Medical University

  • 3:00 PM - 3:20 PM MDT
    Hybrid mechanistic-ML model of Crohn’s disease to predict temporal progression of mucosal damage in patients

    Speaker: Sai Phanindra Venkatapurapu, PhD – AstraZeneca

  • 3:20 PM - 3:30 PM MDT
    Panel - An immune booster: QSP modeling to advance the treatment for autoimmune diseases

    Panelist: Justin S. Feigelman, Dr.rer.nat. (he/him/his) – Gilead Sciences

    Panelist: Douglas W. Chung, M.S. (he/him/his) – Certara Applied BioSimulation, Sheffield, United Kingdom

    Panelist: Chen Zhao, Ph.D. – Nanjing Medical University

    Panelist: Sai Phanindra Venkatapurapu, PhD – AstraZeneca